Triple threat: immunotherapy plus chemo and radiation takes on head and neck cancer
NCT ID NCT07447570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiotherapy can improve outcomes for people with locally advanced head and neck cancer. The study will enroll 27 participants and track how many remain cancer-free after one year. The approach aims to boost the immune system's ability to fight the cancer while using radiation and chemotherapy to shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (immunotherapy drugs) plus chemotherapy (cisplatin) and radiation therapy
What this could lead to
If successful, this combination could offer a more effective treatment for advanced head and neck cancer, potentially lowering the chance of the cancer coming back.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to everyone. The combination of immunotherapy, chemotherapy, and radiation may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••